Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||PRISM: Phase 2 trial with panitumumab monotherapy as second-line treatment in patients with recurrent or metastatic squamous cell carcinoma of the head and neck|
|Citation:||Head and Neck: journal for the sciences and specialities of the head and neck, 2016; 38(S1):E1756-E1761|
|Danny Rischin, David R. Spigel, Douglas Adkins, Richard Wein, Susanne Arnold, Nimit Singhal, Oliver Lee, Swami Murugappan|
|Abstract:||Abstract not available|
|Keywords:||recurrent or metastatic squamous cell carcinoma of the head and neck; panitumumab; Panitumumab Regimen In Secondline Monotherapy of Head and Neck Cancer (PRISM) trial; monotherapy; human papillomavirus (HPV); p16|
|Description:||Published online 17 December 2015|
|Rights:||© 2015 Wiley Periodicals, Inc.|
|Appears in Collections:||Aurora harvest 3|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.